Aging
Navigate
Priority Research Paper|Volume 13, Issue 22|pp 24485—24499

Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test

Oleksandr Demidenko1, Diogo Barardo2, Valery Budovskii1, Robb Finnemore3, Francis R. Palmer III3, Brian K. Kennedy2,3,4,5, Yelena V. Budovskaya1
  • 1TruMe Inc., Alameda, CA 94502, USA
  • 2Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University Singapore, Singapore 117456, Singapore
  • 3Ponce de Leon Health, Fernandina, FL 32034, USA
  • 4Centre for Healthy Longevity, National University Health System, Singapore 117456, Singapore
  • 5Singapore Institute for Clinical Sciences, A*STAR, Singapore 117609, Singapore
* Equal contribution
Received: October 5, 2021Accepted: November 15, 2021Published: November 30, 2021

Copyright: © 2021 Demidenko et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The search continues for possible interventions that delay and/or reverse biological aging, resulting in extended healthspan and lifespan. Interventions delaying aging in animal models are well established; however, most lack validation in humans. The length of human lifespan makes it impractical to perform survival analysis. Instead, aging biomarkers, such as DNA methylation (DNAm) clocks, have been developed to monitor biological age. Herein we report a retrospective analysis of DNA methylation age in 42 individuals taking Rejuvant®, an alpha-ketoglutarate based formulation, for an average period of 7 months. DNAm testing was performed at baseline and by the end of treatment with Rejuvant® supplementation. Remarkably, individuals showed an average decrease in biological aging of 8 years (p-value=6.538x10-12). Furthermore, the supplementation with Rejuvant® is robust to individual differences, as indicated by the fact that a large majority of participants decreased their biological age. Moreover, we found that Rejuvant® is of additional benefit to chronologically and biologically older individuals. While continued testing, particularly in a placebo-controlled design, is required, the nearly 8-year reversal in the biological age of individuals taking Rejuvant® for 4 to 10 months is noteworthy, making the natural product cocktail an intriguing candidate to affect human aging.